BriaCell Therapeutics Corp. Common Shares (BCTX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on BriaCell Therapeutics Corp. Common Shares (BCTX) is Moderate Underperform.

The composite score behind that read is -0.36, weighing +0.27 of bullish evidence against -0.41 bearish.

BriaCell Therapeutics Corp. Common Shares last closed at $4.18, +3.47% on the session.

Against the IVW growth benchmark the position is +2.55% over the forecast window.

The read is built from 12 underlying insights — 1 bullish and 11 bearish.

Agreement across those insights is 92%.

16 graded predictions for BCTX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks BriaCell Therapeutics Corp. Common Shares in the 7th percentile on return on equity, where 100 is best.

BriaCell Therapeutics Corp. Common Shares is classified under Health Care / Biotechnology, with a market capitalisation of $35.15M.

StockMap tracks BriaCell Therapeutics Corp. Common Shares as the 291st largest of the 344 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 180 Moderate Underperform, 152 Neutral, 11 Strong Underperform and 1 Moderate Outperform.

On that composite BriaCell Therapeutics Corp. Common Shares ranks 280th of 344 in the group, against a group median of -0.21.